{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:31:14Z","timestamp":1791847874201,"version":"4.3.4"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clobetasol has demonstrated remarkable results in treating melasma within a short time frame; however, its use is limited because of the risk of local side effects. To date, there is no controlled trial on sequential clobetasol\/hydroquinone for melasma. This study aimed to investigate the tolerability and efficacy of 0.05% clobetasol followed by 4% hydroquinone (CLOB\u2010HQ) in comparison to the isolated use of 4% hydroquinone (HQ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A double\u2010blinded, randomized clinical trial involving 50 women with facial melasma was performed. They were directed to apply 0.05% clobetasol every night for 14\u2009days, followed by 4% hydroquinone for 46\u2009days (CLOB\u2010HQ group), or the use of hydroquinone for 60\u2009days (HQ group). Evaluations were carried out at inclusion, and\u00a0after 14 and 60\u2009days of treatment, measuring modified Melasma Area and Severity Index (mMASI), Melasma Quality of Life scale (MELASQoL), and colorimetry. The Global Aesthetic Improvement Scale (GAIS) was assessed by a blinded evaluator.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no difference in the main outcomes at D14 and D60 (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.1). For CLOB\u2010HQ, the mean (CI 95%) reduction in mMASI was 13.2% (5.1\u201321.3%) and 43.1% (32.2\u201354.0%) at D14 and D60, and for HQ, they were 10.6% (5.9\u201327.5%) and 44.8% (33.2\u201352.3%). The MELASQoL, colorimetric luminosity, and GAIS showed a progressive improvement for both groups despite no difference between them. No severe side effects were identified. No cases of telangiectasias, atrophy, or perioral dermatitis were associated with the use of CLOB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The sequential CLOB\u2010HQ regimen was safe and well tolerated, even though its efficacy was not different from HQ after 14 or 60\u2009days of treatment. Based on these findings, the use of clobetasol 14\u2009days before hydroquinone is not advisable for the treatment of melasma.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.17094","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:39:06Z","timestamp":1709033946000},"page":"1221-1226","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sequential therapy with topical clobetasol for 14\u2009days followed by hydroquinone versus hydroquinone alone in facial melasma treatment: a randomized, double\u2010blind, controlled clinical trial"],"prefix":"10.1111","volume":"63","author":[{"given":"Rebecca P.","family":"de Amorim","sequence":"first","affiliation":[{"name":"Faculdade de Medicina de Botucatu UNESP Medical School  Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayla M. C.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu UNESP Medical School  Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cassiano","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, UNIFESP  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C. C.","family":"Esposito","sequence":"additional","affiliation":[{"name":"Universidade do Oeste Paulista, Unoeste, Presidente Prudente  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina O.","family":"Dias","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu UNESP Medical School  Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana F. T.","family":"de Abreu","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu UNESP Medical School  Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-8241","authenticated-orcid":false,"given":"Edil\u00e9ia","family":"Bagatin","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, UNIFESP  Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-9294","authenticated-orcid":false,"given":"H\u00e9lio A.","family":"Miot","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu UNESP Medical School  Botucatu Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000779\u2010x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000780\u20104"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S402168"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000247129"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065851"},{"key":"e_1_2_6_7_1","first-page":"492","article-title":"Linear hypopigmentation and\u00a0cutaneous atrophy following intra\u2010articular steroid injections for de Quervain's tendonitis","volume":"8","author":"Venkatesan P","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229\u20105178.142483"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3315\/jdcr.2017.1240"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806\u20104841.20143063"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806\u20104841.20165014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524\u20104725.2003.29150.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1677\u201054492011000400001"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1590\/s0365\u201005962013000100008"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1590\/1677\u20105449.20210225"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1590\/1677\u20105449.202201502"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1590\/1677\u20105449.210038"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15146"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16896"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17692"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2011.04430.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19784"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.002"},{"key":"e_1_2_6_24_1","first-page":"67","article-title":"Efficacy and safety of a new triple\u2010combination agent for the treatment of facial melasma","volume":"72","author":"Taylor SC","year":"2003","journal-title":"Cutis"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T06:02:41Z","timestamp":1744005761000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/ijd.17094"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17094","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"2024-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}